Oncolytics Biotech appoints Kirk Look to CFO position Oncolytics Biotech announced the appointment of Kirk Look to the role of CFO. Look has served as Oncolytics' Controller since 2003 and has been the CFO of Oncolytics Biotech U.S. Inc. since 2009.
Oncolytics Biotech granted Orphan Drug Designation for REOLYSIN by FDA Oncolytics Biotech announced that the FDA has granted Orphan Drug Designation for its lead product candidate, REOLYSIN, for the treatment of pancreatic cancer. REOLYSIN is Oncolytics' proprietary isolate of the reovirus. Its primary mode of activity is to infect and selectively target tumours with activating Ras pathway mutations and/or over-expressions of Ras pathway elements including, amongst others, EGFR, BRAF and KRAS.